Literature DB >> 32075584

Adverse events in Chinese human immunodeficiency virus (HIV) patients receiving first line antiretroviral therapy.

Lili Dai1, Bin Su1, An Liu1, Hongwei Zhang1, Hao Wu1, Tong Zhang1, Ying Shao1, Jianwei Li1, Jiangzhu Ye1, Shaoli Bai2, Xiaoling Guo2, Lijun Sun3.   

Abstract

BACKGROUND: Although the global human immunodeficiency virus (HIV) epidemic has improved significantly due to antiretroviral treatment (ART), ART-related adverse events (AEs) remain an issue. Therefore, investigating the factors associated with ART-related AEs may provide vital information for monitoring risks.
METHODS: A prospective cohort study was conducted among adult patients (aged 18 years or older) with HIV who received Tenofovir (TDF) + Lamivudine (3TC) + Efavirenz (EFV) as first-line ART regimens. All AEs during the first 12 months of therapy were recorded. Logistic regression analysis was used to identify variables associated with AEs.
RESULTS: Four hundred seventy-four patients receiving TDF+ 3TC+ EFV ART regimens between March 2017 and October 2017 were included in the study analysis. Among them, 472 (99.6%) experienced at least one AE, 436 (92.0%) patients experienced at least one AE within 1 month of treatment, 33 (7.0%) between one and 3 months of treatment, and three (0.6%) patients after 3 months of treatment. The most commonly reported AE was nervous system (95.6%) related, followed by dyslipidemia (79.3%), and impaired liver function (48.1%). Patients with baseline body mass index (BMI) greater than 24 kg/m2 (adjusted OR 1.77, 95%CI 1.03-3.02), pre-existing multiple AEs (adjusted OR 2.72, 95%CI 1.59-4.64), and pre-existing severe AEs (adjusted OR 5.58, 95%CI 2.65-11.73) were at increased odds of developing a severe AE. Patients with baseline BMI greater than 24 kg/m2 (adjusted OR 2.72, 95%CI 1.25-5.89) were more likely to develop multiple AEs.
CONCLUSION: The incidence of ART-related adverse events over a 12-month period in China was high. Baseline BMI greater than 24 kg/m2, pre-existing multiple AEs, and pre-existing severe AEs were shown to be independent risk factors for developing a severe AE.

Entities:  

Keywords:  Adverse events; Antiretroviral therapy; China; HIV

Year:  2020        PMID: 32075584     DOI: 10.1186/s12879-020-4878-2

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


  4 in total

1.  Patient Reported Central Nervous System Adverse Events of Efavirenz-Based Antiretroviral Therapy in People Living with HIV in Northwest Ethiopia.

Authors:  Esileman Abdela Muche; Mekdes Kiflu; Mohammed Biset Ayalew
Journal:  HIV AIDS (Auckl)       Date:  2020-10-20

2.  Dyslipidemia and Associated Factors in Tenofovir Disoproxil Fumarate-Based Regimen Among Human Immunodeficiency Virus-Infected Ethiopian Patients: A Hospital-Based Observational Prospective Cohort Study.

Authors:  Taklo Simeneh Yazie
Journal:  Drug Healthc Patient Saf       Date:  2020-12-04

3.  Derangement of Liver Enzymes, Hyperglycemia, Anemia, and Associated Factors among HIV-Infected Patients Treated with Tenofovir Disoproxil Fumarate-Based Regimen in Ethiopia: A Prospective Cohort Study.

Authors:  Taklo Simeneh Yazie
Journal:  Biomed Res Int       Date:  2021-06-16       Impact factor: 3.411

4.  Nutritional Intervention Reduces Dyslipidemia, Fasting Glucose and Blood Pressure in People Living with HIV/AIDS in Antiretroviral Therapy: A Randomized Clinical Trial Comparing Two Nutritional Interventions.

Authors:  Erika Aparecida Silveira; Marianne Oliveira Falco; Annelisa Silva E Alves de Carvalho Santos; Matias Noll; Cesar de Oliveira
Journal:  Nutrients       Date:  2020-09-28       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.